HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • The HEOR & RWE Marketplace
    • Visit the Market Place
    • On-demand Webinar
  • Industry Events
    • 5 Tips for Trade Show Success
    • HE Innovation Webinar
    • Webinar Services from HealthEconomics.Com
    • View Conferences
    • View Webinars
    • View Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute
You are here: Home / HEOR Feature / ICER Releases Updated Report on Targeted Treatments for Plaque Psoriasis

ICER Releases Updated Report on Targeted Treatments for Plaque Psoriasis

The Institute for Clinical and Economic Review (ICER) on Friday released a Final Condition Update report and Report-at-a-Glance on targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis.

ICER first reviewed treatments for plaque psoriasis in 2016. This update incorporates new clinical data and cost information for previously reviewed therapies, and includes analyses of more recently approved medications guselkumab (Tremfya, Johnson & Johnson), tildrakizumab (Ilumya, Sun Pharma/Merck), and certolizumab pegol (Cimzia, UCB), as well as risankizumab (AbbVie), which is currently being reviewed by the FDA.

ICER’s condition update report was reviewed at a July 2018 public meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC), one of ICER’s three independent evidence appraisal committees. During the meeting, the New England CEPAC votedthat, compared to TNFα inhibitors, both guselkumab and risankizumab offer a superior net health benefit based on currently available evidence.

The Council further voted that evidence was not adequate to show a net health benefit of tildrakizumab compared to TNFα inhibitors, or of the TNFα inhibitor certolizumab pegol over the other subcutaneously-administered TNFα inhibitors (adalimumab and etanercept).

“Similar to the findings of our 2016 report, we again found that many targeted therapies offer benefit over non-targeted therapies, and we are able to further clarify which agents may be most effective,” ICER CSO Dan Ollendorf said in a statement.

To read the full press release on ICER’s website, click here.



You might also be interested in:

  • Using AI, NLP and Data Visualization with RWE to Generate… 06/10/2020
  • Jeff Anderson Joins OPEN Health as European Lead for OPEN VIE… 06/16/2020
  • Are Healthcare Prices in the U.S. Too High, Too Low, or Both? 08/25/2020
  • Addressing the Affordability Crisis of Cell & Gene Therapies 12/16/2020
  • Robert Dubois, MD, PhD, Steps in as Interim President and CEO… 09/01/2020
  • Patient Drug Costs Increased as Health Plans Promote… 08/07/2020
  • Key Innovations Coming From The Next Generation of PBM’s 08/12/2020

 

View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Conference of the Week:

Link of the Week:

Job of the Week:

Webinar of the Week:

White Papers

  • Whitepaper: The Role of Centralized Care Management in Value-based Care
  • 2017 In-Depth Outlook on Oncology Report
  • Value-Based Healthcare: Making it Happen
  • Value-Based Contracting for Biopharmaceuticals Moves Forward
  • ICER Releases White Paper on Gene Therapy

Syndicated Reports

  • HTA in Europe: Key Success Factors for Positive HTA Recommendations
  • Paying for Digital Health: Payer Insights
  • Benchmarking Pharma’s MSL Capabilities
  • Biosimilars: US Payer Perspectives
  • KAM Metrics: Driving Efficiency, Measuring Success
HealthEconomics.Com

HealthEconomics.Com

  • News
  • Conferences
  • Reports
  • Jobs
  • Consulting
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Webinar Services
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HE Institute

Strategy, Training, Education, and Communications in HEOR & Market Access.

Innovation Webinar

Big ideas accelerating change in HEOR, RWE and Health Technology. Learn more!

tHEORetically Speaking Blog

Insights and observations for HEOR, market access, pricing, reimbursement, and health policy.

HE Jobs Portal

Your Premier Employment Source for HEOR, Market Access, and Real World Evidence

HE Webinars

Online educational and informational seminars for HEOR, market access, pricing, and reimbursement.
  • HealthEconomics.Com
  • About HealthEconomics.Com
  • Advertising Inquiries
  • Careers
  • Contact HealthEconomics.Com

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • The HEOR & RWE Marketplace
    • Visit the Market Place
    • On-demand Webinar
  • Industry Events
    • 5 Tips for Trade Show Success
    • HE Innovation Webinar
    • Webinar Services from HealthEconomics.Com
    • View Conferences
    • View Webinars
    • View Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute